Expansion of the Advanced Medical and Biopharmaceutical CDMO Business
First written in FY2018. 6 of 24 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In fiscal 2025, it entered into a technology license agreement with Astellas Pharma Inc. concerning the development and manufacture of ADC active pharmaceutical ingredients.」
It advanced the CDMO business toward high-value-added services using proprietary technologies and gave concrete form to external expansion through joint culture-medium development with Forge and an ADC active pharmaceutical ingredient technology license with Astellas Pharma Inc. - 2026-05-07Cited as achievedRevision of earnings forecasts
「Bio-pharma services (CDMO) posted higher revenue excluding the impact of the sale of Ajinomoto Althea, Inc.」
Reported higher revenue excluding the impact of the sale of Althea in the bio-pharma services (CDMO) business after the sale. - FY2026-H1ReframedAnnual report
「The group will continue to pursue greater value creation in its businesses by focusing on CDMO operations that use its proprietary technologies, thereby accelerating growth and improving profitability in the healthcare field.」
Following the transfer of Althea and the acquisition of Forge, it clarified its direction of focusing on high-value-added services using proprietary technologies rather than expanding the CDMO business uniformly. - FY2025-H1AdvancedAnnual report
「Through its consolidated subsidiary Ajinomoto North America Holdings, now Ajinomoto North America, the company acquired all equity interests in Forge Biologics Holdings, LLC, a U.S. gene-therapy CDMO, on 21 December 2023 local time. Forge and its subsidiaries became consolidated subsidiaries of the company. The business combination had been accounted for provisionally in the previous consolidated fiscal year, but the accounting was finalized in the current interim consolidated fiscal period.」
The provisional purchase accounting for the acquisition of Forge was finalized in the interim period. In the healthcare and other segment, Bio-Pharma Services posted lower business profit due to the impact of consolidating Forge, despite higher CDMO sales. - FY2024AchievedAnnual report
「Through its consolidated subsidiary Ajinomoto North America Holdings, the company acquired all equity interests in Forge Biologics Holdings, LLC, a U.S. gene-therapy CDMO, on 21 December 2023 local time. Forge and its 5 subsidiaries became consolidated subsidiaries of the company.」
It completed the acquisition of all equity interests in Forge and acquired AAV and plasmid DNA manufacturing capabilities for gene-therapy CDMO, as well as high-purity, high-yield AAV vector production technology. - FY2024-Q3AdvancedAnnual report
「Through its consolidated subsidiary Ajinomoto North America Holdings, the company acquired all equity interests in Forge Biologics Holdings, LLC, a U.S. gene-therapy CDMO, on 21 December 2023 local time. Forge and its 5 subsidiaries became consolidated subsidiaries of the company.」
It completed the acquisition of all equity interests in Forge on 21 December 2023 and made Forge and its 5 subsidiaries consolidated subsidiaries. It acquired end-to-end manufacturing capabilities for gene-therapy CDMO and established a concrete platform for expansion into advanced healthcare and cell therapy. - FY2024-Q2Second-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥139.5 billion, ¥12.1 billion below the same period of the previous year, or 92.0% year on year, due to the impact of lower sales of Functional Materials, including electronic materials, and pharmaceutical- and food-use amino acids. Business profit was ¥10.9 billion, ¥17.9 billion below the same period of the previous year, or 38.0% year on year, as both Functional Materials, including electronic materials, and Bio-Pharma Services & Ingredients posted lower profit.」
The healthcare and other segment posted cumulative second-quarter business profit of ¥10.9 billion due to lower revenue and profit from electronic materials, pharmaceutical- and food-use amino acids, CDMO services and other businesses. - FY2024-Q1First-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥72.1 billion, ¥1.4 billion below the same period of the previous year, or 98.0% year on year, as the effect of lower electronic-materials sales more than offset higher revenue from Bio-Pharma Services & Ingredients.」
Bio-Pharma Services (CDMO) posted higher revenue due to increased sales, while lower electronic-materials sales resulted in lower revenue for the healthcare and other segment overall. - FY2023AdvancedAnnual report
「Revenue in the healthcare and other segment was ¥299.6 billion, ¥48.4 billion higher than in the previous fiscal year, or 119.3% year on year, due to increased sales of Bio-Pharma Services & Ingredients, Functional Materials, including electronic materials, and other businesses, as well as the impact of foreign exchange translation. Business profit was ¥52.5 billion, ¥9.1 billion higher than in the previous fiscal year, or 121.1% year on year, due to the effect of higher revenue, the impact of foreign exchange translation and other factors.」
Healthcare and other revenue rose to ¥299.6 billion and business profit to ¥52.5 billion, driven by increased sales of CDMO services, pharmaceutical- and food-use amino acids, electronic materials and other products. - FY2023-Q3Third-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥227.7 billion, ¥45.8 billion higher than in the same period of the previous year, or 125.2% year on year, due to increased sales of Bio-Pharma Services & Ingredients, Functional Materials and other businesses, as well as the impact of foreign exchange translation. Business profit was ¥45.0 billion, ¥11.7 billion higher than in the same period of the previous year, or 135.2% year on year, due to the effect of higher revenue, the impact of foreign exchange translation and other factors.」
The healthcare and other segment posted third-quarter cumulative revenue of ¥227.7 billion and business profit of ¥45.0 billion, driven by increased sales of Bio-Pharma Services & Ingredients, Functional Materials and other businesses. - FY2023-Q2Second-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥151.6 billion, ¥29.6 billion higher than in the same period of the previous year, or 124.3% year on year, due to increased sales of Bio-Pharma Services & Ingredients, Functional Materials and other businesses, as well as the impact of foreign exchange translation. Business profit was ¥30.8 billion, ¥8.0 billion higher than in the same period of the previous year, or 135.1% year on year, due to the effect of higher revenue, the impact of foreign exchange translation and other factors.」
Cumulative second-quarter revenue in the healthcare and other segment was ¥151.6 billion and business profit was ¥30.8 billion, driven by increased sales of Bio-Pharma Services & Ingredients, Functional Materials and other businesses, as well as foreign exchange effects. - FY2023-Q1First-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥73.6 billion, ¥10.0 billion higher than in the same period of the previous year, or 115.8% year on year, due to increased sales of Bio-Pharma Services & Ingredients and Functional Materials and the impact of foreign exchange translation. Business profit was ¥15.2 billion, ¥2.5 billion higher than in the same period of the previous year, or 120.2% year on year, due to the effect of higher revenue.」
The healthcare and other segment posted revenue of ¥73.6 billion and business profit of ¥15.2 billion, driven by increased sales of Bio-Pharma Services & Ingredients and Functional Materials. - FY2022Full-year results updateAnnual report
「Revenue in the healthcare and other segment was ¥251.2 billion, ¥11.7 billion higher than in the previous fiscal year, or 104.9% year on year, as increased revenue from Bio-Pharma Services & Ingredients and Functional Materials more than offset lower revenue from animal nutrition due to structural reforms. Business profit was ¥43.3 billion, ¥17.0 billion higher than in the previous fiscal year, or 165.1% year on year, due to the effect of higher revenue.」
Full-year business profit in the healthcare and other segment rose substantially to ¥43.3 billion, driven by higher revenue from Bio-Pharma Services & Ingredients and Functional Materials. - FY2022-Q3Third-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥181.9 billion, ¥14.4 billion higher than in the same period of the previous year, or 108.6% year on year, as substantial revenue growth from Bio-Pharma Services & Ingredients and Functional Materials more than offset lower revenue from animal nutrition due to structural reforms. Business profit was ¥33.3 billion, ¥14.9 billion higher than in the same period of the previous year, or 180.9% year on year, due to the effect of higher revenue.」
The healthcare and other segment posted revenue of ¥181.9 billion and business profit of ¥33.3 billion, driven by higher revenue from Bio-Pharma Services & Ingredients and Functional Materials. Animal nutrition posted lower revenue due to the impact of structural reforms. - FY2022-Q2Second-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥121.9 billion, ¥11.3 billion higher than in the same period of the previous year, or 110.2% year on year, as substantial revenue growth from Bio-Pharma Services & Ingredients and Functional Materials more than offset lower revenue from animal nutrition due to structural reforms. Business profit was ¥22.8 billion, ¥10.9 billion higher than in the same period of the previous year, or 191.2% year on year, due to the effect of higher revenue.」
The healthcare and other segment posted revenue of ¥121.9 billion and business profit of ¥22.8 billion, driven by higher revenue from Bio-Pharma Services & Ingredients and Functional Materials. - FY2022-Q1First-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥63.5 billion, ¥9.5 billion higher than in the same period of the previous year, or 117.7% year on year, as substantial revenue growth from Bio-Pharma Services & Ingredients and Functional Materials more than offset lower revenue from animal nutrition due to structural reforms. Business profit was ¥12.7 billion, ¥5.2 billion higher than in the same period of the previous year, or 170.0% year on year, due to the effect of higher revenue.」
The healthcare and other segment posted revenue of ¥63.5 billion and business profit of ¥12.7 billion, driven by higher revenue from Bio-Pharma Services & Ingredients and Functional Materials. - FY2021Full-year results updateAnnual report
「Amino acids posted higher overall revenue due to increased sales of pharmaceutical- and food-use amino acids and the impact of foreign exchange translation on Bio-Pharma Services and other factors.」
The healthcare and other segment posted revenue of ¥239.5 billion and business profit of ¥26.2 billion. Pharmaceutical- and food-use amino acids posted higher revenue and profit, while Bio-Pharma Services posted lower profit due to shipment timing, foreign exchange translation and other factors. - FY2021-Q3Third-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥167.4 billion, ¥1.1 billion below the same period of the previous year, or 99.3% year on year, as substantial revenue growth from chemicals was more than offset by lower revenue from animal nutrition and a substantial decline in sports nutrition. Business profit was ¥18.4 billion, ¥6.0 billion higher than in the same period of the previous year, or 149.3% year on year, reflecting substantial profit growth in animal nutrition and chemicals.」
The healthcare and other segment posted lower segment revenue because, although higher revenue and profit from chemicals contributed positively, revenue declined due to the timing of shipments by Bio-Pharma Services and other factors. - FY2021-Q2Second-quarter results updatedAnnual report
「Amino acids posted lower revenue due to the timing of shipments by Bio-Pharma Services and other factors.」
In the amino-acid-related business, including advanced healthcare and biopharmaceutical CDMO, the timing of shipments by Bio-Pharma Services and other factors contributed to lower revenue in the cumulative second-quarter consolidated period. - FY2021-Q1First-quarter results updatedAnnual report
「Revenue in the healthcare and other segment was ¥54.0 billion, ¥3.4 billion below the same period of the previous year, or 94.0% year on year, as substantial revenue growth from chemicals was more than offset by a substantial decline in animal nutrition and lower revenue from amino acids and other businesses. Business profit was ¥7.4 billion, ¥3.4 billion higher than in the same period of the previous year, or 183.7% year on year, reflecting substantial profit growth in chemicals and animal nutrition. • Amino acids posted lower revenue due to the impact of foreign exchange translation and the timing of shipments by Bio-Pharma Services and other factors.」
The healthcare and other segment posted revenue of ¥54.0 billion and business profit of ¥7.4 billion, while Bio-Pharma Services was a factor behind lower revenue due to shipment timing and other factors. - FY2020-Q3Third-quarter results updatedAnnual report
「Healthcare segment revenue was ¥97.0 billion, ¥1.0 billion higher than in the same period of the previous year, or 101.1% year on year, as higher revenue from pharmaceutical- and food-use amino acids and pharmaceutical custom services more than offset lower revenue from health-based foods and cosmetic ingredients. Business profit was ¥7.6 billion, ¥0.2 billion higher than in the same period of the previous year, or 103.6% year on year, due to substantial profit growth from pharmaceutical- and food-use amino acids.」
The healthcare segment posted revenue of ¥97.0 billion and business profit of ¥7.6 billion, with increased sales of pharmaceutical- and food-use amino acids and pharmaceutical custom services contributing to higher revenue. - FY2019AdvancedAnnual report
「• The CDMO businesses in Europe and the United States, or Contract Development & Manufacturing Organization services commissioned by pharmaceutical companies for development and manufacturing, were integrated under the “AJINOMOTO BIO・PHARMA SERVICES” brand, creating a structure for providing integrated services globally.」
For the advanced healthcare and biopharmaceutical CDMO business, it integrated the brands of its European and U.S. operations and established an integrated global operating structure. - FY2019-Q3AdvancedAnnual report
「Healthcare segment revenue was ¥95.9 billion, ¥12.1 billion higher than in the same period of the previous year, or 114.6% year on year, as pharmaceutical custom services and pharmaceutical- and food-use amino acids posted substantial revenue growth. Business profit was ¥7.4 billion, ¥1.5 billion higher than in the same period of the previous year, or 126.5% year on year, as pharmaceutical- and food-use amino acids and pharmaceutical custom services posted substantial profit growth alongside higher revenue.」
The healthcare business, including advanced healthcare and biopharmaceutical CDMO, posted revenue of ¥95.9 billion and business profit of ¥7.4 billion, reflecting higher revenue and profit from pharmaceutical custom services and other businesses. - FY2018First statedAnnual report
「It decided to expand the development and manufacturing facilities of GeneDesign, Inc. and Ajinomoto Althea to grow its contract development and manufacturing business in advanced healthcare-related fields, including oligonucleotides and next-generation antibody drugs.」
It decided to expand the facilities of GeneDesign and Ajinomoto Althea to grow its contract development and manufacturing business for oligonucleotides, next-generation antibody drugs and other products.